Often it turns out that the price increases by Valeant and Turing that have provoked the most criticism have been on drugs that are off - patent —
meaning generic competitors are free to enter the market, typically bringing the price that most people pay for the drugs way down.
Not exact matches
To start with, the finding that the
generics were potential
competitors meant that the agreements were comparable to market exclusion agreements; such agreements are among the most serious restrictions of competition as they constitute an extreme form of market sharing and of limitation of production.